GlassScriptPhysician profile
Gregory Alan Foster
NPI 1609912070
$7,034.84
in general payments reported to CMS, 2019-2025
28 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $761 · 2020: $267 · 2021: $1,114 · 2022: $1,215 · 2023: $1,546 · 2024: $1,046 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,555 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,554.62 |
| Education | $123.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $797.70 | 2020-2025 | Caplyta |
| Alkermes, INC. | $760.93 | 2022-2025 | Lybalvi, Aristada |
| Lundbeck LLC | $647.07 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $632.30 | 2019-2025 | Rexulti, Nuedexta |
| Abbvie INC. | $589.82 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $563.04 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $425.93 | 2021-2025 | Spravato |
| Axsome Therapeutics, INC. | $404.11 | 2022-2025 | Auvelity, Sunosi |
| Sunovion Pharmaceuticals INC. | $398.13 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $375.73 | 2021-2023 | Austedo Xr, Austedo |
| Supernus Pharmaceuticals, INC. | $190.62 | 2024 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $185.32 | 2025 | Cobenfy |
| Jazz Pharmaceuticals INC. | $131.27 | 2019-2021 | |
| Almatica Pharma LLC | $107.25 | 2022-2023 | Loreev Xr, Gralise |
| Corium, LLC | $106.09 | 2022-2023 | Azstarys |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $91.00 | 2020-2024 | |
| Neuronetics, INC. | $76.15 | 2019-2023 | Neurostar Tms Therapy System |
| Vanda Pharmaceuticals INC. | $71.67 | 2025 | Fanapt |
| Eisai INC. | $60.30 | 2021 | |
| Idorsia Pharmaceuticals US INC | $58.85 | 2022-2023 | Quviviq |
| Adlon Therapeutics L.P. | $55.28 | 2019-2020 | |
| Alfasigma USA, INC. | $53.98 | 2021 | |
| Allergan, INC. | $53.43 | 2019-2020 | |
| Shire North American Group INC | $50.42 | 2019 | |
| Bausch Health US, LLC | $49.69 | 2019 | |
| Neurocrine Biosciences, INC. | $42.71 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $31.05 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $25.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.